Amicus Therapeutics (FOLD) halted, news pending
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Amicus (FOLD) Slammed Following Study 011 Update
December 19, 2012 4:36 PM ESTAmicus Therapeutics (Nasdaq: FOLD) shares are getting slammed in late trading following an update on Study 011. Amicus said the study missed its primary endpoint.
Shares are down about 50 percent on resumption.... More
Amicus Therapeutics (FOLD) to resume trading at 4:30PM ET
December 19, 2012 4:27 PM ESTAmicus Therapeutics, Inc. (NASDAQ: FOLD) to resume trading at 4:30PM ET after reporting that a study failed to show statistical benefit.... More
Amicus Therapeutics (FOLD), Glaxo (GSK) Report Study 011 Did Not Achieve Primary Endpoint
December 19, 2012 4:12 PM ESTAmicus Therapeutics (Nasdaq: FOLD) and GlaxoSmithKline plc (NYSE: GSK) announced the 6-month primary treatment period results from the first Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay. Study 011 randomized a total of 67 patients to receive oral migalastat HCl 150 mg or placebo on an every-other-day (QOD) dosing schedule during a 6-month, double-blind primary treatment period.
Reduction of GL-3 Substrate in Kidney Interstitial Capillaries:
... More
